Prevalence of rubella antibodies: comparison between women with pregnancy induced by infertility treatments and those with spontaneous pregnancy by Haruna, Yuria & Suzuki, Shunji
J PREV MED HYG 2020; 61: E553-E555
E553https://doi.org/10.15167/2421-4248/jpmh2020.61.4.1208
 OPEN ACCESS 
Introduction
Infections can impact the reproductive health of women 
and hence may influence pregnancy-related outcomes 
for both the mother and the child. Rubella is usually a 
mild infectious disease, often accompanied by rash. In 
pregnant women, however, rubella infection can result in 
miscarriage, stillbirth and a series of disabilities known 
as congenital rubella syndrome (CRS) [1]. In developed 
countries, rubella vaccination programs have reduced 
the incidence of rubella and CRS [2, 3]. However, wide-
spread rubella epidemics have sometimes occurred in 
Japan. For example, an outbreak of rubella and CRS 
among adult males occurred between 2012 and 2014, 
and a rubella outbreak among adult males has been re-
kindling since 2018 [4, 5]. Indeed, in October, 2018, the 
US Centers for Disease Control and Prevention (CDC) 
issued the following Practice Enhanced Precautions: 
Travelers to Japan should make sure they are vaccinated 
against rubella with the MMR (measles, mumps, and ru-
bella) vaccine before travel, and pregnant women who 
are not protected against rubella through either vacci-
nation or previous rubella infection should not travel to 
Japan during this outbreak [6]. 
Screening and vaccination for rubella infection should 
be a component of pre-conception care, as there is con-
vincing evidence that vaccination against the infection 
before pregnancy prevents neonatal infections [7, 8]. In 
Japan, more than 5% of all pregnancies are the result 
of the implementation of assisted reproductive technol-
ogy (ART) [9]. The period of infertility treatments also 
offers an opportunity for pre-conception care. In Japan, 
infertility treatment is mainly carried out by obstetri-
cians, some of whom, however, may not be aware of the 
importance of CRS prevention during pre-conception 
care. In Japan, rubella antibody titers are measured in all 
pregnant women by means of the hemagglutination in-
hibition (HI) test during the first perinatal examination, 
the cost being borne by the national health service. We 
compared the prevalence of rubella antibodies in women 
who had conceived after infertility treatments and those 
who had conceived spontaneously.
Methods
The study protocol was approved by the Ethics Com-
mittee of the Japanese Red Cross Katsushika Maternity 
Hospital. Informed consent to the retrospective analysis 
of data was obtained from all subjects. Our institute is 
one of the main perinatal centers in Tokyo, Japan, and 
does not carry out any infertility treatments. 
In Japan, all women undergo rubella antibody measure-
ment at public expense during early pregnancy. We re-
viewed the obstetric records of all nulliparous Japanese 
women who had conceived after infertility treatments and 
whose babies had been born at the Japanese Red Cross 
Katsushika Maternity Hospital from 2014 to 2018. Age-
matched nulliparous women who had conceived sponta-
neously and whose first prenatal examination had been 
carried out on the closest date were selected as controls. 
In this study, we compared the prevalence of rubella an-
tibodies in the nulliparous women who had conceived 
after infertility treatments with those measured in the 
control group. Rubella antibody titers < 32, as measured 
by the HI test,  were considered low, in accordance with 
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a previous report by Ozaki et al. [10]. Data are presented 
as numbers (percentage: %) or averages ± standard de-
viation. Statistical analyses were carried out by means of 
the statistical software SAS version 8.02 (SAS Institute, 
Cary, NC, USA).
Results
No differences in socio-demographic characteristics 
emerged between the 2 groups (p > 0.07), as shown in 
Table I. Table II shows rubella antibody titers, as meas-
ured by the HI test. There were no significant differences 
in the rates of women with rubella antibody titers < 8 or 
< 32 between the 2 groups: women who had conceived 
after infertility treatments and those who had conceived 
spontaneously (titer < 8: 4.1 vs. 3.4%, p = 0.58; titer 
< 32: 17.3 vs. 15.3%, p = 0.45, respectively).
Discussion
In terms of rubella antibody titers, this study did not re-
veal any effect of pre-conception care concerning CRS 
in infertility treatment facilities. During the period con-
sidered, the 411 nulliparous pregnant women who had 
undergone infertility treatment were referred from 38 
ART facilities; however, the results of pre-pregnancy ru-
bella antibody tests were reported only in the documents 
provided by two facilities (5.3%). Even though these 
women had attended pregnancy-related medical facili-
ties, they did not seem to have benefited in comparison 
with women who had only undergone complete first ex-
amination. It must be pointed out, however, that some 
of these latter women have recently begun to undergo 
voluntary rubella testing because of the fear of rubella 
infection during pregnancy. Nevertheless, it is very dis-
appointing that obstetricians, who are familiar with the 
risk of CRS, had failed to perform pre-conception care 
regarding rubella infection. There may be various expla-
nations for this.
In our previous study, ART was seen to be associated 
with a lower prevalence of Chlamydia trachomatis (CT) 
infection before pregnancy [11]. Indeed, women who 
require ART may sometimes have a history of CT infec-
tion. However, women may not be checked for a history 
of rubella infection because this is not associated with 
the causes of infertility. Moreover, the fact that the in-
formation leaflet accompanying the rubella vaccine car-
ries a warning that 'women of childbearing age should 
be careful not to get pregnant for about 2 months after 
vaccination' [12] might also have led ART facilities to 
refrain from checking for a history of rubella infection. 
Finally, neither health education nor a past history of 
vaccination were considered in the study, which is a ma-
jor limitation.
Conclusions
Because doctors who treat infertility are also obste-
tricians, we expected women who received infertility 
treatment to have a higher prevalence of rubella anti-
bodies. However, the results showed no difference in 
Tab. II. Rubella antibody titers in nulliparous women who conceived after infertility treatments (n = 411) and those who conceived spontane-
ously (n = 411).
Rubella antibody titer* 
(%)
Women who conceived after infertility 
treatments (%)
Women who conceived spontaneously 
(%)
< 8 17 (4.1) 14 (3.4)
8 18 (4.4) 15 (3.6)
16 36 (8.8) 34 (8.3)
(< 32) 71 (17.3) 63 (15.3)
32 106 (26.8) 91 (22.1)
64 114 (27.7) 126 (30.7)
128 69 (16.8) 81 (19.7)
256 36 (8.8) 29 (7.1)
> 256 15 (3.6) 21 (5.1)
Total 411 411
* Rubella antibody titer measured by hemagglutination inhibition test.
Tab. I. Women socio-demographic features.
Women who conceived after infertility 
treatments (n, %)
Women who conceived spontaneously 
(%)
Nulliparity 411 (100) 411 (100)
Maternal age (years) 37.0 ± 2.1 37.0 ± 2.1
Living in Tokyo 342 (83) 361 (88)
Economic difficulties* 0 (0) 4 (1)
Total 411 411
* Economic difficulties are defined according to the Japanese hospitalization assistance policy system [13].
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rubella antibody titers between the two groups. Given 
that rubella epidemics have frequently occurred in 
Japan, it is necessary to thoroughly implement pre-
conception care concerning the risk CRS for women 
undergoing infertility treatments, especially in Japa-
nese obstetric clinics. We believe that this is the duty 
of the obstetrician, who is most familiar with the risk 
of CRS.
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